BBIO

$70.94

Market ClosedAs of Mar 17, 8:00 PM UTC

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$70.94
Potential Upside
5%
Whystock Fair Value$74.49
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of c...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.75B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.18
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
2.52

Recent News

Simply Wall St.
Mar 15, 2026

A Look At BridgeBio Pharma (BBIO) Valuation After Strong Long Term Returns And Recent Share Pullback

BridgeBio Pharma (BBIO) has drawn fresh attention after recent trading left the stock with a loss of about 8% over the past month and 7% over the past 3 months. See our latest analysis for BridgeBio Pharma. These recent pullbacks sit against a much stronger backdrop, with the share price up sharply over the past year, as reflected in a 1 year total shareholder return of 110.52% and a 3 year total shareholder return of around 4x. If this kind of biotech volatility has your attention, it could...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 13, 2026

BridgeBio Pharma Touts Attruby Uptake, Bayer’s Europe Rollout and 2026-28 Pipeline Timelines at Leerink Conf

BridgeBio Pharma (NASDAQ:BBIO) highlighted accelerating U.S. uptake for its transthyretin (TTR) stabilizer Attruby and laid out key timelines for upcoming launches and pipeline programs during a presentation at the 2026 Leerink Partners Global Healthcare Conference. Chinmay Shukla, the company’s SVP

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
MarketBeat
Mar 13, 2026

BridgeBio Pharma CEO Teases Pipeline Launches, Attruby Momentum, and Pfizer Tafamidis Trial Update

BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar discussed the company’s late-stage pipeline, commercial execution priorities, and the evolving transthyretin amyloid cardiomyopathy (ATTR-CM) market in a conversation with Barclays biotech analyst Elie Merle. Kumar also offered high-level commentary on t

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Insider Monkey
Mar 11, 2026

BridgeBio (BBIO) Soars 13% on Double-Digit Price Target Upgrade

BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the 10 Stocks Investors Are Watching. BridgeBio saw its share prices jump by 13.22 percent on Tuesday to close at $74.32 apiece, as investors took path from an investment firm’s double-digit price target upgrade for its stock. In a market report, JPMorgan raised its price target for BridgeBio […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Investor's Business Daily
Mar 10, 2026

Why BridgeBio Leapfrogged Its 50-Day Line On Pfizer's Patent Shake-Up

BridgeBio stock popped Tuesday on a notable shake-up in the patent battle surrounding Pfizer's rival drug, tafamidis.

BEARISH
Negative press. News cycle fixated on risk factors or misses.